Oral immunization of mice with lactic acid bacteria producing Helicobacter pylori urease B subunit partially protects against challenge with Helicobacter felis

Journal of Infectious Diseases

Volumn 192, Issue 8, 2005, Pages 1441-1449

  Corthésy, Blaise ^a   Boris, Soledad ^b,c   Isler, Patrick ^a   Grangette, Corinne ^b   Mercenier, Annick ^b,d  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b INSTITUT PASTEUR DE LILLE   (France)

^c DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^d NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CHOLERA TOXIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UREASE; UREASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN PRESENTATION; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERIUM DETECTION; BACTERIUM MUTANT; CHRONIC GASTRITIS; CONTROLLED STUDY; DNA DETERMINATION; DRUG DELIVERY SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME SUBUNIT; EXPERIMENTAL MODEL; FEMALE; HELICOBACTER FELIS; HELICOBACTER INFECTION; HELICOBACTER PYLORI; IMMUNIZATION; LACTIC ACID BACTERIUM; LACTOBACILLUS PLANTARUM; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PEPTIC ULCER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; STOMACH ADENOCARCINOMA; WILD TYPE;

EID: 25844507503     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/444425     Document Type: Article

References (51)

1. Mukhopadhyay P. Gastric cancer and lymphoma. Curr Top Microbiol Immunol 1999; 241:57-69.
2. Hatzifoti C, Wren BW, Morrow WJ. Helicobacter pylori vaccine strategies-triggering a gut reaction. Immunol Today 2000; 21:615-9.
3. Eaton KA, Brooks CL, Morgan DR, Krakowka S. Essential role of urease in pathogenesis of gastritis induced by Helicobacter pylori in gnotobiotic piglets. Infect Immun 1991; 59:2470-5.
4. Ferrero RL, Thiberge JM, Kansau I, Wuscher N, Huerre M, Labigne A. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA 1995; 92:6499-503.
5. Corthésy-Theulaz I, Porta N, Glauser M, et al. Oral immunization with Helicobacter pylori urease B subunit as a treatment against Helicobacter infection in mice. Gastroenterology 1995; 109:115-21.
6. Lee CK, Soike K, Hill J, et al. Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine 1999; 17:1493-505.
7. Michetti P, Corthésy-Theulaz I, Davin C, et al. Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology 1994; 107:1002-11.
8. Del Giudice G, Covacci A, Telford JL, Montecucco C, Rappuoli R. The design of vaccines against Helicobacter pylori and their development. Annu Rev Immunol 2001; 19:523-63.
9. Prinz C, Hafsi N, Voland P. Helicobacter pylori virulence factors and the host immune response: implications for therapeutic vaccination. Trends Microbiol 2003; 11:134-8.
10. Michetti P, Kreiss C, Kotloff KL, et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116:804-12.
11. Gomez-Duarte OG, Lucas B, Yan ZX, Panthel K, Haas R, Meyer TF. Protection of mice against gastric colonization by Helicobacter pylori by single oral dose immunization with attenuated Salmonella typhimurium producing urease subunits A and B. Vaccine 1998; 16:460-71.
12. Corthésy-Theulaz I, Hopkins S, Bachmann D, et al. Mice are protected from Helicobacter pylori infection by nasal immunization with attenuated Salmonella typhimurium phoPc expressing urease A and B subunits. Infect Immun 1998; 66:581-6.
13. Kim SY, Doh HJ, Jang MH, Ha YJ, Chung SI, Park HJ. Oral immunization with Helicobacter pylori-loaded poly(D, L-lactide-co-glycolide) nanoparticles. Helicobacter 1999; 4:33-9.
14. Ermak TH, Giannasca PJ, Nichols R, et al. Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med 1998; 188:2277-88.
15. Goto T, Nishizono A, Fujioka T, Ikewaki J, Mifune K, Nasu M. Local secretory immunoglobulin A and postimmunization gastritis correlate with protection against Helicobacter pylori infection after oral vaccination of mice. Infect Immun 1999; 67:2531-9.
16. Blanchard TG, Nedrud JG, Reardon ES, Czinn SJ. Qualitative and quantitative analysis of the local and systemic antibody response in mice and humans with Helicobacter immunity and infection. J Infect Dis 1999; 179:725-8.
17. Ernst PB, Crowe SE, Reyes VE. How does Helicobacter pylori cause mucosal damage? The inflammatory response. Gastroenterology 1997; 113(Suppl 6):S35-42.
18. Ryan EJ, Daly LM, Mills KH. Immunomodulators and delivery systems for vaccination by mucosal routes. Trends Biotechnol 2001; 19:293-304.
19. Wells JM, Mercenier A. Lactic acid bacteria as mucosal delivery system. In: Wood BJ, Warner PJ, eds. Genetics of lactic acid bacteria. New York: Kluwer Academic Publishers, 2003; 261-90.
20. Blum S, Haller D, Pfeifer A, Schiffrin EJ. Probiotics and immune response. Clin Rev Allergy Immunol 2002; 22:287-309.
21. Seegers JF. Lactobacilli as live vaccine delivery vectors: progress and prospects. Trends Biotechnol 2002; 20:508-15.
22. Pavan S, Desreumaux P, Mercenier A. Use of mouse models to evaluate the persistence, safety, and immune modulation capacities of lactic acid bacteria. Clin Diagn Lab Immunol 2003; 10:696-701.
23. Vesa T, Pochart P, Marteau P. Pharmacokinetics of Lactobacillus plantarum NCIMB 8826, Lactobacillus fermentum KLD, and Lactococcus lactis MG 1363 in the human gastrointestinal tract. Aliment Pharmacol Ther 2000; 14:823-8.
24. Grangette C, Müller-Alouf H, Geoffroy MC, Goudercourt D, Turneer M, Mercenier A. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence. Vaccine 2002; 20:3304-9.
25. Palumbo E, Favier C, Deghorain M, et al. Knockout of the alanine racemase gene in Lactobacillus plantarum results in septation defects and cell wall perforation. FEMS Microbiol Lett 2004; 233:131-8.
26. Grangette C, Müller-Alouf H, Hols P, Goudercourt D, Delcour J, Mercenier A. Enhanced mucosal delivery of antigen using cell-wall mutants of lactic acid bacteria. Infect Immun 2004; 72:2731-7.
27. Clayton CL, Wren BW, Mullany P, Topping A, Tabaqchali S. Molecular cloning and expression of Campylobacter pylori species-specific antigens in Escherichia coli K-12. Infect Immun 1989; 57:623-9.
28. Ferain T, Garmyn D, Bernard N, Hols P, Delcour J. Lactobacillus plantarum ldhL gene: overexpression and deletion. J Bacteriol 1994; 176:596-601.
29. Hols P, Slos P, Dutot P, et al. Efficient secretion of the model antigen M6-gp41E in Lactobacillus plantarum NCIMB8826. Microbiology 1997; 143:2733-41.
30. Josson K, Soetaert P, Michiels F, Joos H, Mahillon J. Lactobacillus hilgardii plasmid pLAB1000 consists of two functional cassettes commonly found in other gram-positive organisms. J Bacteriol 1990; 172:3089-99.
31. Sambrook J, Fritsch EF, Maniatis T. In: Nolan C, ed. Molecular cloning. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press, 1989.
32. Houimel M, Mach JP, Corthésy-Theulaz I, Corthésy B, Fisch I. New inhibitors of Helicobacter pylori urease holoenzyme selected from phage-displayed peptide libraries. Eur J Biochem 1999; 262:774-80.
33. Cottet S, Corthésy-Theulaz I, Spertini F, Corthésy B. Microaerophilic conditions permit to mimic in vitro events occurring during in vivo Helicobacter pylori infection and to identify Rho/Ras-associated proteins in cellular signaling. J Biol Chem 2002; 277:33978-86.
34. Berdoz J, Corthésy B. Human polymeric IgA is superior to IgG and single-chain Fv of the same monoclonal specificity to inhibit urease activity associated with Helicobacter pylori. Mol Immunol 2004; 41:1013-22.
35. Stoicov C, Whary M, Rogers AB, et al. Coinfection modulates inflammatory responses and clinical outcome of Helicobacter felis and Toxoplasma gondii infections. J Immunol 2004; 173:3329-36.
36. Jilek S, Walter E, Merkle HP, Corthésy B. Modulation of allergic responses in mice using biodegradable poly(lactide-co-glycolide) microspheres. J Allergy Clin Immunol 2004; 114:943-50.
37. Barbey C, Donatelli-Dufour N, Batard P, Corradin G, Spertini F. Intranasal treatment with ovalbumin but not the major T cell epitope ovalbumin 323-339 generates interleukin-10 secreting T cells and results in the induction of allergen systemic tolerance. Clin Exp Allergy 2004; 34:654-62.
38. Mestecky J, Moro I, Underdown BJ. Mucosal immunoglobulins. In: Ogra PL, Mestecky J, Lamm ME, Strober W, Bienenstock J, McGhee JR, eds. Mucosal immunology. 2nd ed. San Diego: Academic Press, 1999:133-52.
39. Shimoyama T, Everett SM, Dixon MF, Axon AT, Crabtree JE. Chemokine mRNA expression in gastric mucosa is associated with Helicobacter pylori cagA positivity and severity of gastritis. J Clin Pathol 1998; 51:765-70.
40. Guarner F, Malagelada JR. Gut flora in health and disease. Lancet 2003; 361:512-9.
41. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003; 9:175-91.
42. Grangette C, Müller-Alouf H, Goudercourt D, Geoffroy MC, Turneer M, Mercenier A. Mucosal immune responses and protection against tetanus toxin after intranasal immunization with recombinant Lactobacillus plantarum. Infect Immun 2001; 69:1547-53.
43. Reveneau N, Geoffroy MC, Locht C, Chagnaud P, Mercenier A. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations. Vaccine 2002; 20:1769-77.
44. Macfarlane GT, Cummings JH. Probiotics, infection and immunity. Curr Opin Infect Dis 2002; 15:501-6.
45. Marteau PR. Probiotics in clinical conditions. Clin Rev Allergy Immunol 2002; 22:255-73.
46. Enouf V, Langella P, Commissaire J, Cohen J, Corthier G. Bovine rotavirus nonstructural protein 4 produced by Lactococcus lactis is antigenic and immunogenic. Appl Environ Microbiol 2001; 67:1423-8.
47. Lee MH, Roussel Y, Wilks M, Tabaqchali S. Expression of Helicobacter pylori urease subunit B gene in Lactococcus lactis MG1363 and its use as a vaccine delivery system against H. pylori infection in mice. Vaccine 2001; 19:3927-35.
48. Norton PM, Wells JM, Brown HW, Macpherson AM, Le Page RWF. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C. Vaccine 1997; 15:616-9.
49. Jiang W, Baker HJ, Smith BF. Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective. Infect Immun 2003; 71:40-6.
50. Bermudez-Humaran LG, Langella P, Cortes-Perez NG, et al. Intranasal immunization with recombinant Lactococcus lactis secreting murine interleukin-12 enhances antigen-specific Th1 cytokine production. Infect Immun 2003; 71:1887-96.
51. Steidler L, Neirynck S, Huyghebaert N, et al. Biological containment of genetically modified Lactococcus lactis for intestinal delivery of human interleukin 10. Nat Biotechnol 2003; 21:785-9.